Printer Friendly

Mantle cell lymphoma of the prostate.

Author(s): Abuhjar Abdussalam, MBChB, Ronald G. Gerridzen, MD, FRCSC, FACS

Case report

An 82-year-old man presented with increasing symptoms of bladder outlet obstruction. His medical history included repair of an abdominal aortic aneurysm in late 2005 followed by a brief period of urinary retention that spontaneously resolved. He also had hypercholesterolemia and diabetes. He had no family history of prostate cancer and his prostate-specific antigen (PSA) level was 2.4.

Cystoscopy demonstrated a moderately large prostate with a prominent middle lobe and a moderately trabeculated bladder with small diverticula. After medical therapy failed to improve his symptoms he underwent transurethral resection of the prostate. We resected 28 g of tissue with substantial clinical improvement. Microscopically, the tissue was substantially infiltrated by an atypical lymphoid infiltrate positive for CD20, BCL2, CD5 (weakly), κ light chain and cycline D1, consistent with mantle cell lymphoma (Fig. 1 and Fig. 2).

A computed tomography (CT) scan of his abdomen and thorax showed marked lymphadenopathy consistent with stage-IIIA mantle cell lymphoma. He had no constitutional or systemic symptoms. We referred him to a medical oncologist, and he received CHOP/Rituxan chemotherapy.


Lymphoma of the prostate, either primary or secondary, is very rare. Most cases are diagnosed at autopsy. A 20-year review of 1474 patients with prostate cancer was completed at the MD Anderson Cancer Center; only 18 nonleukemic secondary cancers were identified.[sup.1] An autopsy series of 6000 male patients who died of cancer revealed only 185 (3.1%) with metastatic prostate cancer, of which only 49 (0.8%) had non-Hodgkins lymphoma.[sup.2] According to the criteria of Bostwick and colleagues,[sup.2] primary prostatic lymphoma will be diagnosed only if the following criteria are fulfilled: primary symptoms are attributable to prostatic enlargement; the major bulk of disease is localized to the prostate; and lymph nodes, liver or spleen are not involved within 1 month of diagnosis. Therefore, even though our patient presented with symptoms attributable to prostatic enlargement, he should be classified as having secondary prostatic lymphoma. Only 2 cases of mantle cell lymphoma involving the prostate have been reported. The first[sup.3] was reported in December 2003 from the Queen Mary Hospital, University of Hong Kong, and the second[sup.4] in February 2006 from Cleveland.


Our patient had a highly unusual presentation of mantle cell lymphoma involving the prostate. There were no other systemic manifestations of the primary disease, therefore the pathological findings were unsuspected.

Competing interests: None declared.

This paper has been peer-reviewed.


1.. Zein TA, Huben R, Lane W, et al. Secondary tumors of the prostate. J. Urol 1985;133:615-6.

2.. Bostwick DG, Iczkowski KA, Amin MB, et al. Malignant lymphoma involving the prostate: report of 62 cases. Cancer 1998;83:732-8.

3.. Chim CS, Loong F, Yau T, et al. Common malignancies with uncommon sites of presentation case 2: mantle cell lymphoma of the prostate gland. J Clin Oncol 2003;21:4456-8.

4.. Genkin I. Mantle cell lymphoma of prostate. Commun Oncol 2006;3:69.


Fig. 1.: Prostatic tissue infiltrated by an atypical lymphoid infiltrate under low and high power. [Figure omitted]

Fig. 2.: Prostatic tissue infiltrated by an atypical lymphoid infiltrate positive for CD5 (weak), Kappa light chain and cycline D1. [Figure omitted]

Author Affiliation(s):

[1] From the Division of Urology, Department of Surgery, University of Ottawa, Ottawa, Ont

Correspondence: Dr. Ronald G. Gerridzen, The Ottawa Hospital - Civic Campus, Division of Urology, B327, 1053 Carling Ave., Ottawa ON K1Y 4E9;
COPYRIGHT 2009 Canadian Urological Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Abdussalam, Abuhjar; Gerridzen, Ronald G.
Publication:Canadian Urological Association Journal (CUAJ)
Article Type:Case study
Geographic Code:1CANA
Date:Dec 1, 2009
Previous Article:Dose escalation of second-line sunitinib results in rapid partial remission of multiple hepatic metastases.
Next Article:The importance of quality indicators: a call to action.

Related Articles
Utility of Flow Cytometry Immunophenotyping for the Diagnosis and Classification of Lymphoma in Community Hospital Clinical Needle...
Low-Grade B-Cell Lymphoma With Coexpression of Both CD5 and CD10: A Report of 3 Cases.
Small lymphoid proliferations in extranodal locations.
Radiological case of the month: Vani Vijayakumar, MD; Raman Kansal, MD; and Atiar Rahman, MD, PhD.
Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters